Covidien has announced it has completed its acquisition of CV Ingenuity, according to a news release.
Covidien announced in December it would acquire CV Ingenuity, a privately held company based in Fremont, Calif., that describes itself as a "medical device company focused on improving patient outcomes in the treatment of vascular disease by providing solutions to relieve vascular obstructions, inhibit restenosis and allow natural vessel healing." Its core technology is a drug coated balloon platform.
"We are pleased to add both the talented team members at CV Ingenuity as well as their promising DCB technology to our growing portfolio of vascular products," said Stacy Enxing Seng, president, vascular therapies for Covidien, in the release. "We are committed to being the clear first choice for our physician and hospital partners by delivering technology to improve patient outcomes."
Financial terms of the transaction were not disclosed.
Related Articles on Company Acquisitions:
Analogic to Acquire Ultrasonix Medical for $83M
Saint-Gobain Performance Plastics Acquires American Fluoroseal
DJO Global Acquires Exos Corp.